Scottish Medicines Consortium metformin hydrochloride (Glucophage)

Scottish Medicines Consortium metformin hydrochloride (Glucophage)

in the absence of a submission from the holder of the marketing authorisation

metformin hydrochloride (Glucophage SR®) is not recommended for use within NHS Scotland.

Indication under review: Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are:
• at high risk for developing overt type 2 diabetes mellitus and
• still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Name: metformin hydrochloride (Glucophage)
SMC Drug ID: 1308/18
Manufacturer: Merck Serono Ltd
Indication: Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are: • at high risk for developing overt type 2 diabetes mellitus and • still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 15 January 2018

To read more Press Release articles, click here.